Glutamatergic and dopaminergic function and the relationship to outcome in people at clinical high risk of psychosis: a multi-modal PET-magnetic resonance brain imaging study.
Adult
Case-Control Studies
Dopamine
/ metabolism
Female
Follow-Up Studies
Glutamic Acid
/ metabolism
Humans
Longitudinal Studies
Magnetic Resonance Imaging
Magnetic Resonance Spectroscopy
/ methods
Male
Multimodal Imaging
/ methods
Positron-Emission Tomography
/ methods
Psychotic Disorders
/ diagnostic imaging
Risk Factors
Treatment Outcome
Young Adult
Journal
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
ISSN: 1740-634X
Titre abrégé: Neuropsychopharmacology
Pays: England
ID NLM: 8904907
Informations de publication
Date de publication:
03 2020
03 2020
Historique:
received:
17
06
2019
accepted:
23
09
2019
revised:
20
09
2019
pubmed:
17
10
2019
medline:
29
12
2020
entrez:
17
10
2019
Statut:
ppublish
Résumé
Preclinical models of psychosis propose that hippocampal glutamatergic neuron hyperactivity drives increased striatal dopaminergic activity, which underlies the development of psychotic symptoms. The aim of this study was to examine the relationship between hippocampal glutamate and subcortical dopaminergic function in people at clinical high risk for psychosis, and to assess the association with the development of psychotic symptoms.
Identifiants
pubmed: 31618752
doi: 10.1038/s41386-019-0541-2
pii: 10.1038/s41386-019-0541-2
pmc: PMC7021794
mid: EMS85806
doi:
Substances chimiques
Glutamic Acid
3KX376GY7L
Dopamine
VTD58H1Z2X
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
641-648Subventions
Organisme : Wellcome Trust
ID : 200102
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/L022176/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/N027078/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_U120097115
Pays : United Kingdom
Organisme : Medical Research Council
ID : G0700995
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/N026063/1
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 094849
Pays : United Kingdom
Références
Cell Mol Neurobiol. 2006 Jul-Aug;26(4-6):365-84
pubmed: 16773445
Schizophr Res. 2003 Mar 1;60(1):21-32
pubmed: 12505135
Am J Psychiatry. 2011 Apr;168(4):418-26
pubmed: 21159728
Am J Psychiatry. 2016 Apr 1;173(4):392-9
pubmed: 26684922
J Nucl Med. 2006 Dec;47(12):1936-44
pubmed: 17138736
Mol Psychiatry. 2013 Aug;18(8):909-15
pubmed: 22869037
J Neurosci. 2008 Dec 24;28(52):14320-8
pubmed: 19109513
JAMA Psychiatry. 2013 Aug;70(8):793-802
pubmed: 23739772
Biol Psychiatry. 2010 Oct 1;68(7):599-602
pubmed: 20638047
Proc Natl Acad Sci U S A. 1994 Nov 22;91(24):11651-4
pubmed: 7972118
JAMA Psychiatry. 2019 Feb 1;76(2):199-207
pubmed: 30427993
Trends Neurosci. 2019 Mar;42(3):205-220
pubmed: 30621912
Lancet. 2003 Jan 25;361(9354):281-8
pubmed: 12559861
J Neurosci. 2015 Jul 1;35(26):9615-21
pubmed: 26134644
Biol Psychiatry. 2002 Oct 1;52(7):759-63
pubmed: 12372667
Biol Psychiatry. 2009 Sep 15;66(6):533-9
pubmed: 19559402
Schizophr Res. 2011 Sep;131(1-3):184-91
pubmed: 21705195
Mol Psychiatry. 2014 Jan;19(1):20-9
pubmed: 24166406
Schizophr Bull. 2018 Oct 17;44(6):1323-1331
pubmed: 29294102
Schizophr Bull. 2019 Jan 1;45(1):148-157
pubmed: 29385549
Neuropsychopharmacology. 2012 Jan;37(1):4-15
pubmed: 21956446
Neuroimage. 2010 Apr 1;50(2):524-531
pubmed: 20034580
Schizophr Bull. 2017 Mar 1;43(2):293-301
pubmed: 28057720
Psychol Med. 2009 Feb;39(2):179-95
pubmed: 18606047
Mol Psychiatry. 2011 Sep;16(9):885-6
pubmed: 21358709
Arch Gen Psychiatry. 2009 Jan;66(1):13-20
pubmed: 19124684
Neuropsychopharmacology. 2014 Sep;39(10):2397-404
pubmed: 24718373
J Cereb Blood Flow Metab. 1985 Dec;5(4):584-90
pubmed: 4055928
Biol Psychiatry. 2012 Mar 15;71(6):561-7
pubmed: 22133268
J Cereb Blood Flow Metab. 2003 Mar;23(3):285-300
pubmed: 12621304
Schizophr Res. 2012 Dec;142(1-3):217-22
pubmed: 23123134
Schizophr Bull. 1987;13(2):261-76
pubmed: 3616518
Biol Psychiatry. 1999 Jul 1;46(1):56-72
pubmed: 10394474
Neuropsychopharmacology. 2011 Aug;36(9):1781-91
pubmed: 21508933
Biol Psychiatry. 2017 Jan 1;81(1):9-20
pubmed: 27720198
Am J Psychiatry. 2001 Sep;158(9):1367-77
pubmed: 11532718
Int J Neuropsychopharmacol. 2013 Mar;16(2):471-5
pubmed: 22717289
Nat Rev Drug Discov. 2016 Jul;15(7):485-515
pubmed: 26939910
Lancet. 2014 May 10;383(9929):1677-1687
pubmed: 24315522
Aust N Z J Psychiatry. 2005 Nov-Dec;39(11-12):964-71
pubmed: 16343296
Schizophr Bull. 2008 Nov;34(6):1095-105
pubmed: 18718885
Schizophr Bull. 2016 May;42(3):732-43
pubmed: 26591006
Brain. 2013 Nov;136(Pt 11):3242-51
pubmed: 24097339
Transl Psychiatry. 2017 Feb 7;7(2):e1027
pubmed: 28170002
Neuropsychopharmacology. 2014 May;39(6):1479-89
pubmed: 24385130
Schizophr Res. 2009 Mar;108(1-3):69-77
pubmed: 19097753
JAMA Psychiatry. 2017 Dec 1;74(12):1206-1213
pubmed: 29049482
JAMA Psychiatry. 2017 Nov 1;74(11):1104-1111
pubmed: 28973084
Neuropharmacology. 2012 Mar;62(3):1342-8
pubmed: 21621548
Mol Psychiatry. 2015 Apr;20(4):433-9
pubmed: 24912493
Br J Psychiatry. 1995 May;166(5):654-9
pubmed: 7620753
Arch Gen Psychiatry. 2012 Aug;69(8):776-86
pubmed: 22474070
Schizophr Bull. 2013 Jul;39(4):807-14
pubmed: 22282457
Schizophr Bull. 2018 Oct 17;44(6):1301-1311
pubmed: 29301039
Nat Rev Neurosci. 2016 Aug;17(8):524-32
pubmed: 27256556
Arch Gen Psychiatry. 2012 Mar;69(3):220-9
pubmed: 22393215
Schizophr Bull. 2010 May;36(3):455-60
pubmed: 19889950
Am J Psychiatry. 1998 Jun;155(6):761-7
pubmed: 9619147
Proc Natl Acad Sci U S A. 2018 Oct 23;115(43):E10167-E10176
pubmed: 30297411
Curr Top Behav Neurosci. 2010;4:529-53
pubmed: 21312412
J Neurosci. 2007 Oct 17;27(42):11424-30
pubmed: 17942737
Magn Reson Med. 2006 Jun;55(6):1219-26
pubmed: 16688703
J Psychopharmacol. 2015 Feb;29(2):97-115
pubmed: 25586400
Proc Natl Acad Sci U S A. 1996 Aug 20;93(17):9235-40
pubmed: 8799184
Neuron. 2013 Apr 10;78(1):81-93
pubmed: 23583108
Am J Psychiatry. 2011 Dec;168(12):1311-7
pubmed: 21768612
Biol Psychiatry. 2013 Jul 15;74(2):106-12
pubmed: 23312565
Lancet Psychiatry. 2018 Oct;5(10):816-823
pubmed: 30236864
Mol Psychiatry. 2019 Oct;24(10):1502-1512
pubmed: 29679071